Conventional blood-based biomarkers such as CA125 (ovarian cancer) and PSA (prostate cancer) remain in clinical use, yet their effectiveness for early detection is fundamentally constrained by insufficient sensitivity and specificity [8,29]. The gene discussed is KLK3; the disease is prostate carcinoma.